gepotidacin
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Gepotidacin is a first-in-class triazaacenaphthylene antibacterial that inhibits bacterial type II topoisomerases and has in…
Abstract Background The “SPICE organisms” intrinsically produce low levels of a chromosomally encoded β-lactamase enzyme, AmpC…
Abstract Background Gepotidacin (GEP), a first in class novel triazaacenaphthylene bacterial topoisomerase inhibitor, inhibits…
Abstract Background Uncomplicated urinary tract infections (uUTIs) are very common, with approximately 11% of women >18 years of…
Abstract Background At a urology center in Australia, patients undergoing elective nonurgent urological surgery routinely receive…
Abstract Background Leptospirosis is the most widespread zoonotic disease in the world. In India, it is endemic in coast lined…
ABSTRACT Gepotidacin, a novel first-in-class triazaacenaphthylene topoisomerase II inhibitor, was tested against 85 type strains…
Introduction Gepotidacin (GEP), a novel triazaacenaphthylene antibacterial, inhibits bacterial DNA replication. A Phase 2 study…
ABSTRACT This study was conducted to determine the effect of testing parameters on the in vitro activity of gepotidacin, a new…
ABSTRACT Gepotidacin, a novel triazaacenaphthylene antibacterial agent, is the first in a new class of type IIA topoisomerase…